- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06034652
T-GENVIH-003 LTFU (Long Term Follow Up) Study
January 22, 2024 updated by: Integra LifeSciences Corporation
A Prospective Analysis of the Use of Gentrix® Surgical Matrix for Soft Tissue Reinforcement in Ventral Hernia Repair as Long Term Follow Up to T-GENVIH-002 Study
The T-GENVIH-003 study will collect additional, longer term performance data of Gentrix® Surgical Matrix used for reinforcement of ventral hernia repairs from a subset population (i.e., the twenty-one minimally invasive surgical approach cases) from the prior T-GENVIH-002 study.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The purpose of this study is to collect additional safety data and demonstrate the performance of Integra Gentrix® Surgical Matrix for reinforcement of ventral hernia repairs from a sub-population of twenty-one participants from the previous T-GENVIH-002 study, specifically those with laparoscopic or robotic repair.
Prospective data will be collected via a one-off study follow-up visit and assessed for later post-operative surgical site events and complications in the post-operative period from the last timepoint of data collection in T-GENVIH-002 to present.
Study Type
Observational
Enrollment (Actual)
8
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Karen Bartku
- Phone Number: 727.899.0990
- Email: karen.bartku@integralife.com
Study Contact Backup
- Name: Andrew Tummon
- Phone Number: 609.936.5490
- Email: andrew.tummon@integralife.com
Study Locations
-
-
Florida
-
Fort Myers, Florida, United States, 33912
- Surgical Healing Arts
-
Contact:
- Alfredo Mier y Leon
- Phone Number: 239-344-9876
- Email: alfredo@surgicalhealingarts.com
-
Contact:
- Kelsey Vest
- Phone Number: 239.344.9786
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Subjects from the sub-population of minimally invasive surgical approach (e.g., laparoscopic or robotic) ventral hernia repair of the prior T-GENVIH-002 study.
Description
Inclusion Criteria:
- Patient was a subject in the T-GENVIH-002 study and underwent minimally invasive (i.e., laparoscopic or robotic) abdominal wall reconstruction for a primary hernia using Integra® Gentrix® Surgical Matrix.
- Subject has participated in the informed consent process and signed a study-specific informed consent document.
- Subject is fluent in US English or US Spanish language.
- Subject is willing to complete an e-consent and phone or in-office visit.
Exclusion Criteria:
- Not applicable.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Prospective Analysis of Minimally Invasive Surgical Approach (i.e., laparoscopic or robotic)
Collection of performance data for twenty-one subjects having prior minimally invasive surgical approach for ventral hernia repair (i.e., laparoscopic or robotic) from the previous T-GENVIH-002 study last data collection time-point (1-yr post-op) to present (prospective analysis), not previously reported.
|
Integra® Gentrix® Surgical Matrix is intended for implantation to reinforce soft tissue where weakness exists in patients requiring gastroenterological or plastic & reconstructive surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinically Confirmed Recurrence
Time Frame: 1 year to present
|
1. Incidence of clinically confirmed recurrence of the primary hernia to date, including not previously reported in T-GENVIH-002 study.
|
1 year to present
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-Reported Recurrence
Time Frame: 1 year to present
|
Incidence of self-reported recurrence (i.e., bulge) of the primary hernia to date, including not previously reported in T-GENVIH-002 study.
|
1 year to present
|
Incidence of Surgical Site Occurrences requiring Procedural Intervention (SSOPI)
Time Frame: 1 year to present
|
Incidence of Surgical Site Occurrences requiring Procedural Intervention (SSOPI) of the primary hernia repair to date, including not previously reported in T-GENVIH-002.
|
1 year to present
|
Incidence of Surgical Site Occurrences (SSOs)
Time Frame: 1 year to present
|
Incidence of Surgical Site Occurrences (SSOs) of the primary hernia repair to date (seroma, abscess, dehiscence, hematoma, wound necrosis, ileus, fistula, delayed wound healing), including not previously reported in T-GENVIH-002 study.
|
1 year to present
|
Incidence of Surgical Site Infections (SSIs)
Time Frame: 1 year to present
|
Incidence of Surgical Site Infections (SSIs) post primary hernia repair to date, including not previously reported in T-GENVIH-002 study.
|
1 year to present
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Adam Young, PhD PMP, Integra LifeSciences Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 12, 2023
Primary Completion (Actual)
January 19, 2024
Study Completion (Actual)
January 19, 2024
Study Registration Dates
First Submitted
September 6, 2023
First Submitted That Met QC Criteria
September 6, 2023
First Posted (Actual)
September 13, 2023
Study Record Updates
Last Update Posted (Estimated)
January 23, 2024
Last Update Submitted That Met QC Criteria
January 22, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- T-GENVIH-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hernia
-
University of NebraskaLifeCellCompletedHiatal Hernia | Esophageal Hernia | Hernia, Esophageal | Hernia, Paraesophageal | Paraesophageal Hiatal Hernia | Sliding Esophageal Hernia | Sliding Hiatal HerniaUnited States
-
Advanced Medical Solutions Ltd.CompletedInguinal Hernia | Hernia | Femoral Hernia | Groin HerniaUnited States
-
Medtronic - MITGCompletedInguinal Hernia | Ventral HerniaUnited States
-
Mette Astrup MadsenCompletedInguinal Hernia | Femoral HerniaDenmark
-
W.L.Gore & AssociatesRecruitingHernia, Hiatal | Hernia, Diaphragmatic | Hernia, Ventral | Incisional HerniaUnited States
-
Hobart HarrisWithdrawnHernia | Ventral Hernia | Abdominal Hernia
-
Anne Arundel Health System Research InstituteMedtronic - MITGCompletedGrade I Ventral Hernia | Grade II Ventral HerniaUnited States
-
Foregut Research FoundationNot yet recruitingParaesophageal Hernia | Large Hiatal HerniaUnited States
-
AbbVieNot yet recruiting
-
Prisma Health-UpstateRecruiting
Clinical Trials on Integra® Gentrix® Surgical Matrix
-
Hamilton Health Sciences CorporationAFP Innovation Fund; Stem Cell Network; Ontario Institute for Regenerative MedicineNot yet recruiting
-
University of South FloridaIntegra LifeSciences CorporationTerminated
-
Georgetown UniversityLifeNet HealthUnknownWounds | Chronic Wounds | Nonmalignant ConditionUnited States
-
HealthPartners InstituteTerminated
-
University Hospital, BordeauxCompletedLeg Injuries | Ankle Injuries | Foot InjuriesFrance
-
Mayo ClinicTerminatedBarretts Esophagus With High Grade Dysplasia | Barrett AdenocarcinomaUnited States
-
Integra LifeSciences CorporationCompletedNeuropathic Diabetic Ulcer - FootUnited States, Netherlands Antilles
-
Zhejiang Xingyue Biotechnology Co., Ltd.CompletedDonor Site WoundChina
-
Istituti Clinici Scientifici Maugeri SpACompleted
-
Walter Reed National Military Medical CenterUnknown